KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research annual meeting on Monday, April 8 and highlighted as part of the official meeting press...

Related Keywords

United States ,Texas ,American ,Scott Kopetz ,Anne Kerber ,Bristol Myers Squibb ,American Association For Cancer Research ,Twitter ,European Commission ,Exchange Commission ,Youtube ,University Of Texas Md Anderson Cancer Center ,Department Of Gastrointestinal Medical Oncology ,Mirati Therapeutics Inc ,Linkedin ,Facebook ,Instagram ,Cancer Research ,Gastrointestinal Medical Oncology ,Cell Therapy ,Bristol Myers ,Prescription Drug User Fee Act ,Myers Squibb ,Mirati Therapeutics ,Prescribing Information ,Better Future ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,